Pharmacological activation of Peroxisome proliferator-activated receptor improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice

H. T. Wu, C. T. Chen, K. C. Cheng, Y. X. Li, C. H. Yeh, J. T. Cheng

研究成果: 雜誌貢獻文章同行評審

20 引文 斯高帕斯(Scopus)

摘要

The mechanisms regarding hepatic steatosis related to hepatic insulin resistance have been well documented. However, the agents for treatment of hepatic steatosis and insulin resistance remain poorly developed. Peroxisome proliferator-activated receptors (PPARs) are transcription factors that are responsible for the regulation of glucose and/or lipid metabolism. There are 3 distinct isoforms of PPARs family: PPAR, PPAR, and PPAR. Both PPAR and PPAR agonists are widely used in clinic for the treatment of hyperlipidemia and hyperglycemia. However, the therapeutic efficacy of PPAR agonists for diabetic disorders remains obscure. In the present study, we used L-165041as PPAR agonist to treat the high fat diet (HFD) fed mice. Administration of L-165041 improved the hepatic steatosis and increased the insulin sensitivity in HFD-mice. In addition to the histological identification of hepatic steatosis, the improvement of insulin sensitivity was characterized by the enhanced insulin signals and the increase of hepatic glycogen content. This is the first report showing that pharmacological activation of PPAR improves insulin resistance in diet-induced diabetic mice. Thus, we suggest that pharmacological activation of PPAR may be a new strategy for the treatment of diabetic patients with hepatic steatosis.
原文英語
頁(從 - 到)631-635
頁數5
期刊Hormone and Metabolic Research
43
發行號9
DOIs
出版狀態已發佈 - 7月 4 2011
對外發佈

ASJC Scopus subject areas

  • 內分泌學、糖尿病和代謝
  • 生物化學
  • 內分泌
  • 臨床生物化學
  • 生物化學(醫學)

指紋

深入研究「Pharmacological activation of Peroxisome proliferator-activated receptor improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice」主題。共同形成了獨特的指紋。

引用此